Search research articles
Contact Us
Filters
Showing results (21-30 of 240) with videos related to
Page
of 24
Sort By:
Future Oncology (London, England)
|
July 23, 2015
Should vascular effects of newer treatments be addressed more completely?
Eric H Yang, Karol E Watson, Joerg Herrmann
European Journal of Preventive Cardiology
|
February 24, 2021
Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!
Ragavendra R Baliga, Eric H Yang, Eduardo Bossone
Current Oncology Reports
|
May 29, 2020
The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
Ishan Asokan, Soniya V Rabadia, Eric H Yang
Journal of the American College of Cardiology
|
December 4, 2010
A superinfected pulmonary valve myxoma
Eric H Yang, Andrew A Zadeh, Jina Chung
The American Journal of Medicine
|
March 27, 2012
Digitalis toxicity: a fading but crucial complication to recognize
Eric H Yang, Sonia Shah, John M Criley
JACC. Cardiooncology
|
January 17, 2026
Defining the Name of the Game in Exercise Oncology: How Do We Incentivize Physical Activity?
Enat Arega, Christina M Dieli-Conwright, Eric H Yang
Journal of the American Heart Association
|
December 16, 2021
Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes
Rachel E Ohman, Eric H Yang, Melissa L Abel
Annals of Internal Medicine
|
October 18, 2006
Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction
Henry H Ting, Eric H Yang, Charanjit S Rihal
Heart Failure Clinics
|
June 19, 2022
T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies
Ashley F Stein-Merlob, Sarju Ganatra, Eric H Yang
Circulation
|
November 25, 2016
Response by Herrmann et al to Letter Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue"
Joerg Herrmann, Eric H Yang, Cezar Iliescu, et al.
Page
of 24
Search research articles
Search
Showing results (21-30 of 240) with videos related to
Sort By:
Page
of 24
Future Oncology (London, England)
|
July 23, 2015
Should vascular effects of newer treatments be addressed more completely?
Eric H Yang, Karol E Watson, Joerg Herrmann
European Journal of Preventive Cardiology
|
February 24, 2021
Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!
Ragavendra R Baliga, Eric H Yang, Eduardo Bossone
Current Oncology Reports
|
May 29, 2020
The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
Ishan Asokan, Soniya V Rabadia, Eric H Yang
Journal of the American College of Cardiology
|
December 4, 2010
A superinfected pulmonary valve myxoma
Eric H Yang, Andrew A Zadeh, Jina Chung
The American Journal of Medicine
|
March 27, 2012
Digitalis toxicity: a fading but crucial complication to recognize
Eric H Yang, Sonia Shah, John M Criley
JACC. Cardiooncology
|
January 17, 2026
Defining the Name of the Game in Exercise Oncology: How Do We Incentivize Physical Activity?
Enat Arega, Christina M Dieli-Conwright, Eric H Yang
Journal of the American Heart Association
|
December 16, 2021
Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes
Rachel E Ohman, Eric H Yang, Melissa L Abel
Annals of Internal Medicine
|
October 18, 2006
Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction
Henry H Ting, Eric H Yang, Charanjit S Rihal
Heart Failure Clinics
|
June 19, 2022
T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies
Ashley F Stein-Merlob, Sarju Ganatra, Eric H Yang
Circulation
|
November 25, 2016
Response by Herrmann et al to Letter Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue"
Joerg Herrmann, Eric H Yang, Cezar Iliescu, et al.
Page
of 24